Pfizer COVID-19 vaccine safety data - Child participants COVID-19 vaccines Main navigation COVID-19 vaccines Moderna XBB.1.5 COVID-19 vaccine Pfizer XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix® Data on this page show the responses of individuals aged 5–11 years who received a paediatric 5–11 years formulation of the Pfizer COVID-19 vaccine (both monovalent original and XBB.1.5 variant) and whose parent or carer completed an AusVaxSafety survey on their behalf sent on day 3 after vaccination. These data provide a profile of what to expect in the days following a child’s Pfizer COVID-19 vaccination and can assist when planning for a child’s COVID-19 vaccination. Data on this page are updated monthly. AusVaxSafety’s active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration (TGA). Find out more about how the TGA monitors the safety of vaccines and how you can report side effects on the TGA website. News & events All news & events 08 November 2024 | News Enhanced National Immunisation Program vaccine safety data now available 23 October 2024 | News AusVaxSafety study affirms short-term safety profile of Moderna and Novavax COVID-19 vaccine priming doses 01 October 2024 | News AusVaxSafety marks a decade of progress in vaccine safety 12 September 2024 | News AusVaxSafety surveillance of 2024 seasonal flu vaccines concludes with no safety issues identified